STAT+: Supreme Court’s gutting of Chevron doctrine could mean headaches for drug industry

STAT June 29, 2024
Nicholas Florko, Lizzy Lawrence, John Wilkerson, Elaine Chen

The Food and Drug Administration’s power to make important regulatory decisions is in question after a Supreme Court decision weakening federal agencies’ ability to interpret ambiguous statutory measures. The ruling could mean headaches not just for the teams of lawyers and scientists at the FDA, but for the drug and device companies the agency is charged with regulating.

While the Supreme Court’s decision is not expected to have major implications on the FDA’s bread and butter task —...

Today's Sponsors

Today's Sponsor